{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,22]],"date-time":"2026-03-22T09:27:49Z","timestamp":1774171669432,"version":"3.50.1"},"reference-count":26,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1016\/j.jaad.2015.07.018","type":"journal-article","created":{"date-parts":[[2015,9,12]],"date-time":"2015-09-12T11:42:16Z","timestamp":1442058136000},"page":"802-808","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"title":["Improvement of tuberous sclerosis complex (TSC) skin tumors during long-term treatment with oral sirolimus"],"prefix":"10.1016","volume":"73","author":[{"given":"Neera","family":"Nathan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji-an","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaowei","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward W.","family":"Cowen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary","family":"Haughey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joel","family":"Moss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas N.","family":"Darling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2015.07.018_bib1","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1056\/NEJMoa063564","article-title":"Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis","volume":"358","author":"Bissler","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2015.07.018_bib2","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1056\/NEJMoa1001671","article-title":"Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis","volume":"363","author":"Krueger","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2015.07.018_bib3","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1056\/NEJMoa1100391","article-title":"Efficacy and safety of sirolimus in lymphangioleiomyomatosis","volume":"364","author":"McCormack","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2015.07.018_bib4","doi-asserted-by":"crossref","first-page":"4071","DOI":"10.1158\/1078-0432.CCR-11-0445","article-title":"Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangioleiomyomatosis: a phase 2 trial","volume":"17","author":"Davies","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jaad.2015.07.018_bib5","doi-asserted-by":"crossref","first-page":"797","DOI":"10.7326\/0003-4819-154-12-201106210-00007","article-title":"Changes in lung function and chylous effusions in patients with lymphangioleiomyomatosis treated with sirolimus","volume":"154","author":"Taveira-DaSilva","year":"2011","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jaad.2015.07.018_bib6","doi-asserted-by":"crossref","first-page":"e23379","DOI":"10.1371\/journal.pone.0023379","article-title":"Multicenter phase 2 trial of sirolimus for tuberous sclerosis: kidney angiomyolipomas and other tumors regress and VEGF- D levels decrease","volume":"6","author":"Dabora","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.jaad.2015.07.018_bib7","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1212\/WNL.0b013e3182815428","article-title":"Everolimus long-term safety and efficacy in subependymal giant cell astrocytoma","volume":"80","author":"Krueger","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.jaad.2015.07.018_bib8","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0140-6736(12)61134-9","article-title":"Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicenter, randomized, placebo-controlled phase 3 trial","volume":"381","author":"Franz","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2015.07.018_bib9","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0140-6736(12)61767-X","article-title":"Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicenter, randomized, double-blind, placebo-controlled trial","volume":"381","author":"Bissler","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2015.07.018_bib10","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1002\/ana.23960","article-title":"Everolimus treatment of refractory epilepsy in tuberous sclerosis complex","volume":"74","author":"Krueger","year":"2013","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jaad.2015.07.018_bib11","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1093\/ndt\/gfu013","article-title":"The effect of everolimus on renal angiomyolipoma in patients with tuberous sclerosis complex being treated for subependymal giant cell astrocytoma: subgroup results from the randomized, placebo-controlled, phase 3 trial EXIST-1","volume":"29","author":"Kingswood","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.jaad.2015.07.018_bib12","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/S1470-2045(14)70489-9","article-title":"Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomized EXIST-1 study","volume":"15","author":"Franz","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jaad.2015.07.018_bib13","series-title":"Tuberous Sclerosis Complex","first-page":"285","article-title":"Dermatologic manifestations of tuberous sclerosis complex (TSC)","author":"Darling","year":"2010"},{"key":"10.1016\/j.jaad.2015.07.018_bib14","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1046\/j.1440-0960.2001.00488.x","article-title":"Bexarotene capsules and gel for previously treated patients with cutaneous T-cell lymphoma: results of the Australian patients treated on phase II trials","volume":"42","author":"Prince","year":"2001","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.jaad.2015.07.018_bib15","first-page":"581","article-title":"Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma","volume":"137","author":"Duvic","year":"2001","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2015.07.018_bib16","doi-asserted-by":"crossref","first-page":"3539","DOI":"10.1073\/pnas.0712397105","article-title":"Mesenchymal-epithelial interactions involving epiregulin in tuberous sclerosis complex hamartomas","volume":"105","author":"Li","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaad.2015.07.018_bib17","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1093\/hmg\/ddt597","article-title":"Sun exposure causes somatic second-hit mutations and angiofibroma development in tuberous sclerosis complex","volume":"23","author":"Tyburczy","year":"2014","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.jaad.2015.07.018_bib18","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.pediatrneurol.2013.08.001","article-title":"Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference","volume":"49","author":"Northrup","year":"2013","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.jaad.2015.07.018_bib19","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1001\/jamadermatol.2014.938","article-title":"Dermatologic and dental aspects of the 2012 International Tuberous Sclerosis Complex Consensus Statements","volume":"150","author":"Teng","year":"2014","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2015.07.018_bib20","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/ncomms1236","article-title":"Human TSC2-null fibroblast-like cells induce hair follicle neogenesis and hamartoma morphogenesis","volume":"2","author":"Li","year":"2011","journal-title":"Nat Commun"},{"key":"10.1016\/j.jaad.2015.07.018_bib21","doi-asserted-by":"crossref","first-page":"897025","DOI":"10.1155\/2013\/897025","article-title":"Mammalian target of rapamycin inhibitors induce tumor cell apoptosis in\u00a0vivo primarily by inhibiting VEGF expression and angiogenesis","volume":"2013","author":"Frost","year":"2013","journal-title":"J Oncol"},{"key":"10.1016\/j.jaad.2015.07.018_bib22","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1046\/j.1365-4362.1998.00495.x","article-title":"Skin lesions in children with tuberous sclerosis complex: their prevalence, natural course, and diagnostic significance","volume":"37","author":"Jozwiak","year":"1998","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2015.07.018_bib23","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s11523-011-0167-8","article-title":"Mechanisms of mTOR inhibitor resistance in cancer therapy","volume":"6","author":"Carew","year":"2011","journal-title":"Target Oncol"},{"key":"10.1016\/j.jaad.2015.07.018_bib24","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1056\/NEJMoa1403352","article-title":"Response and acquired resistance to everolimus in anaplastic thyroid cancer","volume":"371","author":"Wagle","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2015.07.018_bib25","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/ajd.12125","article-title":"Topical rapamycin for angiofibromas in pediatric patients with tuberous sclerosis: follow-up of a pilot study and promising future directions","volume":"55","author":"Tu","year":"2014","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.jaad.2015.07.018_bib26","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.pediatrneurol.2014.02.016","article-title":"Topical everolimus for facial angiofibromas in the tuberous sclerosis complex. A first case report","volume":"51","author":"Dill","year":"2014","journal-title":"Pediatr Neurol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962215019325?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962215019325?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:35:28Z","timestamp":1759271728000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962215019325"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["S0190962215019325"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2015.07.018","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2015,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Improvement of tuberous sclerosis complex (TSC) skin tumors during long-term treatment with oral sirolimus","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2015.07.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Mosby, Inc.","name":"copyright","label":"Copyright"}]}}